SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Hjorth Hansen H) srt2:(2010-2014)"

Sökning: WFRF:(Hjorth Hansen H) > (2010-2014)

  • Resultat 1-4 av 4
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  • Baccarani, Michele, et al. (författare)
  • European LeukemiaNet recommendations for the management of chronic myeloid leukemia : 2013
  • 2013
  • Ingår i: Blood. - : American Society of Hematology. - 0006-4971 .- 1528-0020. ; 122:6, s. 872-884
  • Forskningsöversikt (refereegranskat)abstract
    • Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase inhibitors, mandate regular updating of concepts and management. A European LeukemiaNet expert panel reviewed prior and new studies to update recommendations made in 2009. We recommend as initial treatment imatinib, nilotinib, or dasatinib. Response is assessed with standardized real quantitative polymerase chain reaction and/or cytogenetics at 3, 6, and 12 months. BCR-ABL1 transcript levels <= 10% at 3 months, <1% at 6 months, and <= 0.1% from 12 months onward define optimal response, whereas >10% at 6 months and >1% from 12 months onward define failure, mandating a change in treatment. Similarly, partial cytogenetic response (PCyR) at 3 months and complete cytogenetic response (CCyR) from 6 months onward define optimal response, whereas no CyR (Philadelphia chromosome-positive [Ph1]>95%) at 3 months, less than PCyR at 6 months, and less than CCyR from 12 months onward define failure. Between optimal and failure, there is an intermediate warning zone requiring more frequent monitoring. Similar definitions are provided for response to second-line therapy. Specific recommendations are made for patients in the accelerated and blastic phases, and for allogeneic stem cell transplantation. Optimal responders should continue therapy indefinitely, with careful surveillance, or they can be enrolled in controlled studies of treatment discontinuation once a deeper molecular response is achieved. (Blood. 2013; 122(6):872-884)
  •  
3.
  •  
4.
  • Mustjoki, S, et al. (författare)
  • Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients
  • 2013
  • Ingår i: Leukemia. - : Springer Science and Business Media LLC. - 0887-6924 .- 1476-5551. ; 27:7, s. 1520-1526
  • Tidskriftsartikel (refereegranskat)abstract
    • Chronic myeloid leukemia (CML) stem cells appear resistant to tyrosine kinase inhibitors (TKIs) in vitro, but their impact and drug sensitivity in vivo has not been systematically assessed. We prospectively analyzed the proportion of Philadelphia chromosome-positive leukemic stem cells (LSCs, Ph+CD34+CD38=) and progenitor cells (LPCs, Ph+CD34+CD38+) from 46 newly diagnosed CML patients both at the diagnosis and during imatinib or dasatinib therapy (ClinicalTrials.gov NCT00852566). At diagnosis, the proportion of LSCs varied markedly (1-100%) between individual patients with a significantly lower median value as compared with LPCs (79% vs 96%, respectively, P = 0.0001). The LSC burden correlated with leukocyte count, spleen size, hemoglobin and blast percentage. A low initial LSC percentage was associated with less therapy-related hematological toxicity and superior cytogenetic and molecular responses. After initiation of TKI therapy, the LPCs and LSCs rapidly decreased in both therapy groups, but at 3 months time point the median LPC level was significantly lower in dasatinib group compared with imatinib patients (0.05% vs 0.68%, P = 0.032). These data detail for the first time the prognostic significance of the LSC burden at diagnosis and show that in contrast to in vitro data, TKI therapy rapidly eradicates the majority of LSCs in patients.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-4 av 4
Typ av publikation
tidskriftsartikel (2)
konferensbidrag (1)
forskningsöversikt (1)
Typ av innehåll
refereegranskat (4)
Författare/redaktör
Simonsson, Bengt (2)
Mustjoki, S (2)
Malm, Claes (1)
Fioretos, Thoas (1)
Lindblom, A (1)
Wadenvik, Hans, 1955 (1)
visa fler...
Barbany, G (1)
Olsson, Bob, 1969 (1)
Thunberg, Sarah, 197 ... (1)
Stromberg, U (1)
Gedde-Dahl, T. (1)
Ehrencrona, Hans (1)
Ehrencrona, H (1)
Simonsson, B. (1)
Almqvist, S (1)
Kantarjian, Hagop M. (1)
Richter, Johan (1)
Olsson-Strömberg, Ul ... (1)
Baccarani, Michele (1)
Rosti, Gianantonio (1)
Saussele, Susanne (1)
Steegmann, Juan Luis (1)
Mayer, Jiri (1)
Clark, Richard E. (1)
Pane, Fabrizio (1)
Niederwieser, Dietge ... (1)
Saglio, Giuseppe (1)
Cervantes, Francisco (1)
Guilhot, François (1)
Hochhaus, Andreas (1)
Hjorth-Hansen, Henri ... (1)
Martinelli, Giovanni (1)
Deininger, Michael W ... (1)
Soverini, Simona (1)
Apperley, Jane F. (1)
Cortes, Jorge E. (1)
Hughes, Timothy P. (1)
Kim, Dong-Wook (1)
Larson, Richard A. (1)
Lipton, Jeffrey H. (1)
Mahon, Francois-Xavi ... (1)
Mueller, Martin C. (1)
Radich, Jerald P. (1)
Rousselot, Philippe (1)
Schiffer, Charles (1)
Silver, Richard (1)
Goldman, John M. (1)
Hehlmann, Ruediger (1)
Nagler, A (1)
Jönsson, Sofia (1)
visa färre...
Lärosäte
Uppsala universitet (2)
Göteborgs universitet (1)
Umeå universitet (1)
Kungliga Tekniska Högskolan (1)
Linköpings universitet (1)
Lunds universitet (1)
visa fler...
Karolinska Institutet (1)
visa färre...
Språk
Engelska (4)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (2)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy